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Background: New-onset diabetes after transplantation (NODAT) is a serious complication following liver 
transplantation (LT). The present study aimed to investigate the incidence of and risk factors for NODAT 
using the Korean Organ Transplantation Registry (KOTRY) database. 
Methods: Patients with history of pediatric transplantation (age ≤18 years), re-transplantation, multi-organ 
transplantation, or pre-existing diabetes mellitus were excluded. A total of 1,919 non-diabetic adult patients 
who underwent a primary LT between May 2014 and December 2017 were included. Risk factors were 
identified using Cox regression analysis. 
Results: NODAT occurred in 19.7% (n=377) of adult liver transplant recipients. Multivariate analysis 
showed steroid use, increased age, and high body mass index (BMI) in recipients, and implantation of a left-
side liver graft was closely associated with NODAT in adult LT. In living donor liver transplant (LDLT) 
patients (n=1,473), open donor hepatectomy in the living donors, steroid use, small for size liver graft (graft 
to recipient weight ratio ≤0.8), increased age, and high BMI in the recipient were predictive factors for 
NODAT. The use of antimetabolite and basiliximab induction reduced the incidence of NODAT in adult LT 
and in adult LDLT. 
Conclusions: Basiliximab induction, early steroid withdrawal, and antimetabolite therapy may prevent 
NODAT after adult LT. High BMI or advanced age in liver recipients, open donor hepatectomy in living 
donors, and small size liver graft can predict the occurrence of NODAT after adult LT or LDLT.
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Introduction
Advancements in surgical techniques for liver transplantation 
(LT), optimization of immunosuppressive regimens 
and perioperative monitoring methods are improving 
the survival of LT recipients. Thus, key post-transplant 
concerns are now long-term complications and quality of 
life after LT as opposed to short-term complications and 
perioperative mortality in the past. 
New-onset diabetes after transplantation (NODAT) 
is currently the most common postoperative metabolic 
complication after LT (1). NODAT refers to the development 
of post-transplant diabetes in previously non-diabetic 
patients (i.e., patients who are not diabetic before 
transplantation, but show sustained high blood glucose 
levels after transplantation and meet the World Health 
Organization diagnostic criteria for diabetes). The 
development of NODAT is closely associated with acute 
rejection, infection, chronic cardiovascular disease, chronic 
renal insufficiency and decreased graft survival, all of which 
are leading causes of mortality among LT recipients (2-10). 
In addition, patients who develop NODAT have increased 
health care costs (1,2,11). However, the mechanisms 
underlying NODAT after LT has not been investigated 
extensively and NODAT after LT has received less attention 
compared to NODAT after kidney transplantation. 
NODAT is a serious complication of LT that negatively 
affects patients’ health and graft survival. The reported 
incidence of NODAT after LT ranges from 9% to 
63.3% (5).
Multiple risk factors for NODAT in liver transplant 
recipients have been reported: increased recipient age, 
African–American ethnicity, hepatitis C virus (HCV) 
infection, advanced liver cirrhosis, liver graft from deceased 
donor, tacrolimus use, alcoholic liver disease, steroid 
use, high body mass index (BMI), hypomagnesemia, 
biopsy-proven acute rejection, and cytomegalovirus 
infection (1,5,9,12).
Studies based on national registries and other administrative 
datasets have made enormous contributions to the science of 
organ transplantation. The Korean Organ Transplantation 
Registry (KOTRY) is a nationwide prospective cohort 
designed to play an academically oriented role beyond that 
of just an administrative registry. The KOTRY compiles 
and analyzes at regular intervals demographic and clinical 
information of new liver transplant patients and donors, 
as well as data on the use of immunosuppressive drugs, 
post-operative outcomes and other endpoints (13,14). 
In 2015, there were 44 liver transplant centers in Korea, 
among which 15 participated in the KOTRY. Due to a 
high number of large-volume centers joining the KOTRY, 
77.1% of LT performed annually were enrolled in the 
KOTRY database.
Data regarding the risk factors, incidence, and clinical 
consequences of NODAT in Korean liver transplant 
recipients are lacking. Nearly 70% of liver transplants 
recorded in the KOTRY have been from living donors; 
the risk factors for NODAT in KOTRY are likely to be 
inconsistent with the risk factors identified in studies based 
on deceased donor liver transplantation (DDLT) (1,2,12). 
Using the KOTRY database, we aimed to investigate the 
occurrence of NODAT in South Korea, to evaluate its 
impact on prognosis of graft survival and identify possible 
risk factors for NODAT. We present the following article in 




The study population comprised of patients who 
underwent LT between April 2014 and December 2017 
(n=2,648). The KOTRY organizational structure, patient 
enrollment and informed consent have been described in 
previous reports (15,16). Patients with history of pediatric 
transplantation (age ≤18 years), re-transplantation, multi-
organ transplantation, or pre-existing diabetes mellitus 
were excluded. A total of 1,919 patients without pre-
existing diabetes were included in the final study cohort. 
Both donors and recipients were required to register with 
the KOTRY before transplantation. All registered patients 
were routinely followed up at their outpatient clinic. This 
study was approved by the KOTRY, which is the only 
authorized national LT registry in South Korea. The study 
was initiated after obtaining approval from the ethics 
committee for each participating center, according to the 
Regulations on Human Organ Transplant and national legal 
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requirements. The procedures were in accordance with 
the Helsinki declaration. All patients provided informed 
consent prior to participation in the study.
Definition of NODAT 
The presence of diabetes as a co-morbid condition prior 
to transplantation was identified by querying the KOTRY 
database entries for our patient population. NODAT 
was defined using the American Diabetes Association 
(ADA) diagnostic criteria: an fating plasma glucose level 
≥126 mg/dL (7.0 mmol/L), symptoms of polyuria, 
polydipsia and/or unexplained weight loss, a random plasma 
glucose concentration of ≥200 mg/dL, and an HbA1c value 
of ≥6.5% (17). Fasting was defined as no caloric intake 
for at least 8 hours. Glomerular filtration rate (GFR) was 
calculated using the MDRD equation (18). CKD in the 
post-transplant was defined as more than stage 3 (GFR 
<60 mL/min).
The presence of NODAT was identified in the previously 
non-diabetic transplant recipients when at least one record 
of diabetes was entered in the follow-up reports after LT. If 
diabetes disappeared after steroid withdrawal or 6 months 
in the post-transplant, we did not define NODAT case in 
those patients. The date of onset of NODAT was assumed 
to be the date of the earliest report of diabetes after liver 
transplant.
Data collection in recipients and donors, and transplant-
related factors
We assessed the following recipient-related risk factors; 
gender, age, history of hypertension, pre-transplant BMI 
(kg/m2), primary liver disease, hepatocellular carcinoma 
(HCC), Child-Pugh class, Model for End-stage Liver 
Disease (MELD) scores for chronic liver disease or 
cirrhosis, urgent status in Korean Network for Organ 
Sharing (KONOS), and serum creatinine levels at 1 month, 
6 months, 1 year, 2 years, and 3 years. Donor-related 
factors included donor gender, presence of hypertension or 
diabetes, and BMI. Transplant-related factors included LT 
type (DDLT or LDLT), ABO-incompatibility, liver graft 
(whole liver, left-side liver graft, or right-side liver graft), 
macrosteatosis in the donor liver, living related donor, 
surgical approach in living liver donor (open or minimal 
invasive approach, including laparoscopic or robotic donor 
hepatectomy), small size liver graft [graft to recipient weight 
ratio (GRWR) ≤0.8], hospitalization after LT, basiliximab 
induction, selection of calcineurin inhibitors (tacrolimus 
or cyclosporine) at discharge, use of antimetabolite 
(mycophenolate mofetil or mycophenolic acid) or steroid at 
discharge, and use of mTOR inhibitors at 6 months.
The current KONOS system utilizes an urgent DDLT 
allocation system for adult patients similar to that used by 
the previous United Network for Organ Sharing (UNOS) 
system. UNOS status 1 including early retransplantation 
and status 2A categories are identical to KONOS status 
1 and status 2A, respectively (19). Patients with known 
hepatitis B virus (HBV) infection cannot be KONOS status 
1 due to the high prevalence of HBV in Korea and difficulty 
in discerning acute liver failure from acute-on-chronic liver 
failure in these patients.
Statistical analysis
Continuous data are expressed as the mean ± SD. Statistical 
comparisons were made using independent t-tests for 
normally distributed data. Continuous variables, including 
donor and recipient BMI, MELD score, and macrosteatosis 
in liver grafts were categorized since their effects on 
outcomes are not linear. Categorical data are expressed as 
numbers or percentages and the significance of differences 
between groups was analyzed using the chi-square test 
or Fisher’s exact test. Kaplan-Meier curves were used to 
represent allograft survival. Diabetes-free survival rates 
were estimated by the Kaplan-Meier method using the log-
rank test. Patient death, graft loss, re-transplantation, and 
loss to follow-up were censored in the diabetes-free survival 
analyses. Univariate and multivariate analyses for predicting 
NODAT development were performed using a Cox 
proportional hazard model. All P values were two-tailed, 
and a P value at or below 0.05 was considered statistically 
significant. All statistical analyses were performed using 
SAS version 9.4 (SAS, Inc., Cary, NC, USA) and SPSS ver. 
22.0 (SPSS, Inc., Chicago, IL, USA).
Results
The incidence of NODAT
NODAT occurred in 377 (19.7%) of 1,919 liver recipients 
with a mean follow-up time of 13.1±10.6 months. The 
incidence of NODAT was 19.6% and 20.8% at 6 and 
12 months after LT, respectively (Figure 1). A total of 
447 (23.3%) and 1,472 (76.7%) patients received DDLT 
and LDLT, respectively. The incidence of NODAT in 
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the LDLT group was greater than in the DDLT group 
(P=0.031).
The recipient, donor, and immunosuppression variables 
according to the presence of NODAT are summarized 
in Table 1. The recipients who developed NODAT were 
older, had higher BMI, and included a greater proportion 
of living-related donors, open donor hepatectomy, and 
small size liver grafts (GRWR ≤0.8) compared with patients 
without NODAT. With regard to immunosuppression, the 
proportion of basiliximab induction, cyclosporine use, and 
steroid use in patients with NODAT was greater than in 
patients without NODAT, but antimetabolite use in the 
patients with NODAT was lower than in patients without 
NODAT (Table 1).
Risk factors for NODAT
Multivariate analyses showed that increased recipient age, 
high recipient BMI, implantation of left-side liver graft, 
and steroid use were predisposing factors for developing 
NODAT in adult LT patients, whereas basiliximab 
induction and antimetabolite use were significantly 
associated with a decreased risk of NODAT (Table 2). In 
DDLT patients, increased recipient age (HR, 1.028; 95% 
CI, 1.005–1.052; P=0.020) was only an independent factor 
for NODAT (Table S1). In LDLT patients, increased 
recipient age, high recipient BMI, Child-Pugh class, 
small size liver grafts (GRWR ≤0.8), and steroid use were 
predisposing factors for NODAT, but the presence of 
HCC, minimally invasive donor hepatectomy, basiliximab 
induction, and antimetabolite use were closely associated 
with protective effects against NODAT (Table 3). 
Graft survival 
We found no significant difference in terms of the graft 
survival rates between patients with NODAT and patients 
without NODAT (Figure 2). In fact, we found that the graft 
survival rates in patients with NODAT were similar to those 
in patients without NODAT after DDLT and LDLT. 
Discussion
In this study using the KOTRY liver transplant database, 
NODAT was reported in 19.7% of recipients of an initial 
liver graft with a median follow-up time of 1 year. In fact, 
most of the NODAT cases in this study (90%) reported 
within 6 months after liver transplant. The incidence of 
diabetes is 10.22% in middle-aged Koreans (20). Therefore, 
the incidence of NODAT is higher than that of diabetes 
in general population. A study based on the Organ 
Procurement and Transplant Network/United Network for 
Organ Sharing (OPTN/UNOS) liver transplant database 
showed that NODAT occurred in 26.4% of liver recipients 
with a median follow-up of about 2 years, and more than 
80% of NODAT occurred within 1 year after LT. The onset 
Figure 1 NODAT incidence. (A) New-onset diabetes after transplantation (NODAT) incidence in adult liver recipients and (B) NODAT 
incidence in DDLT and LDLT recipients.
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Table 1 Comparison of transplant patients with and without NODAT
Variables No NODAT (n=1,542) NODAT (n=377) P value
Recipient gender (male) 1,081 (70.1) 276 (73.2) 0.256
Recipient age 52.7±9.4 54.8±8.1 <0.001
Recipient hypertension 103 (6.7) 23 (6.1) 0.816
Recipient body mass index 23.8±3.6 24.6±3.8 <0.001
Body mass index in recipient <0.001
<18.5 69 (4.5) 20 (5.3)
18.5–25 953 (61.9) 196 (52.0)
25–30 433 (28.1) 129 (34.2)
>30 85 (5.5) 32 (8.5)
Unknown 2 (1.3) –
Primary liver disease 0.496
HBV 892 (57.8) 214 (56.8)
HCV 107 (6.9) 30 (8.0)
Alcoholic 351 (22.8) 89 (23.6)
Cryptogenic 66 (4.3) 21 (5.6)
Others 126 (8.2) 23 (6.1)
Hepatocellular carcinoma 772 (50.1) 175 (46.4) 0.207
Child-Pugh class 0.883
A 477 (30.9) 103 (27.3)
B 462 (30.0) 141 (37.4)
C 603 (39.1) 133 (35.3)
MELD score 17.8±10.4 17.4±9.3 0.657
MELD score 0.589
<15 775 (50.3) 189 (50.1)
15–34 592 (38.4) 158 (41.9)
≥35 175 (11.3) 30 (8.0)
Urgent status in KONOS 0.151
1 35 (2.3) 9 (2.4)
2 123 (8.0) 17 (4.5)
3 91 (5.9) 26 (6.9)
4 253 (16.4) 58 (15.4)
5 1,040 (67.4) 267 (70.8)
ABO-incompatible 236 (15.3) 68 (18.0) 0.208
Table 1 (continued)
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Table 1 (continued)
Variables No NODAT (n=1,542) NODAT (n=377) P value
Liver graft 0.344
Whole 355 (23.0) 71 (18.8)
Left-side graft 46 (3.0) 21 (5.6)
Right-side graft 1,141 (74.0) 285 (75.6)
Donor macrosteatosis (%) 4.2±6.6, 2 [0–58] 4.1±7.0, 1 [0–58] 0.366
Macrosteatosis in donor 0.464
<10% 1,197 (77.6) 313 (83.0)
10–30% 186 (12.1) 46 (12.2)
>30% 32 (2.1) 5 (1.3)
Unknown 127 (8.2) 13 (3.4)
Hospitalization (days) 28.3±22.8 28.0±23.6 0.201
Follow-up durations (months) 12.9±10.7 14.0±9.8 0.011
Living donor liver transplantation (n=1,472) 1,170 302
Relationship in LDLT <0.001
Living-related donor 901 (77.0) 275 (91.1)
Living-unrelated donor 269 (23.0) 27 (8.9)
Living donor operation (minimally invasive surgery) 184 (15.7) 28 (9.3) 0.004
GRWR 1.17±0.31 1.13±0.31 0.008
GRWR >0.8 in LDLT 1,062 (90.8) 258 (85.4) 0.003
Basiliximab induction 1,205 (78.1) 270 (71.8) 0.008
Tacrolimus at discharge 1,325 (85.9) 367 (97.3) 0.946
Cyclosporine at discharge 15 (1.1) 10 (2.7) 0.046
Antimetabolite at discharge 1,165 (75.6) 259 (68.7) 0.007
Steroids at discharge 1,359 (88.1) 362 (96.0) <0.001
Use of mTOR inhibitors at 6 months post-transplant 170 (11.0) 35 (9.3) 0.353
Donor gender (male) 991 (64.3) 233 (61.8) 0.371
Donor age (years) 35.3±14.3 34.0±13.0 0.228
Hypertension in donor 103 (6.7) 23 (6.1) 0.644
Diabetes in donor 49 (3.2) 10 (2.7) 0.475
Donor body mass index 23.2±3.2 23.3±3.0 0.484
Donor body mass index 0.095
<18.5 73 (4.7) 15 (4.0)
18.5–25 1,063 (68.9) 276 (73.2)
25–30 358 (23.2) 78 (20.7)
>30 47 (3.0) 8 (2.1)
Unknown 1 (0.1) –
Data are shown as mean ± standard deviation or number (percentage).
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Table 2 Risk factors for NODAT in adult liver transplant patients (n=1,919)
Variables
Univariate Multivariate
HR 95% CI P value HR 95% CI P value
Recipient gender (male) 1.17 0.931–1.469 0.178
Recipient age 1.024 1.012–1.036 <0.001 1.022 1.010–1.034 <0.001
Hypertension in recipients 1.346 1.035–1.750 0.027
Body mass index in recipients 0.003 0.003
<18.5 1 1 1 1
18.5–24 0.728 0.460–1.153 0.729 0.458–1.159
25–29 1.029 0.642–1.648 1.028 0.638–1.656
≥30 1.245 0.712–2.177 1.242 0.706–2.185
Primary liver disease 0.452
Alcohol 1 1
Cryptogenic 1.259 0.782–2.025
Hepatitis B virus 0.946 0.739–1.212
Hepatitis C virus 1.057 0.699–1.599
Others 0.733 0.463–1.159
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of diabetes within the first 6 months of LT has been found 
to be associated with high doses of corticosteroid, and with 
immune suppression due to other medications and physical 
inactivity (1,4,5,7,10,12,21,22). 
The reported incidence of NODAT after LT ranges 
from 7% to 30%; the differences between study results may 
have been due to differences in diagnostic criteria, statistical 
methods, use of immunosuppressive agents, the length of 
follow-up and study populations (1,4,9,10). The timing of 
diagnostic screening for NODAT is also important. Almost 
all patients will have post-operative hyperglycemia due 
to the stress of surgery and administration of high-dose 
steroids. In addition, post-transplant patients may suffer 
from surgical complications, infections, and other comorbid 
conditions in the first year, leading to hospitalizations and 




HR 95% CI P value HR 95% CI P value
Donor type (LDLT) 1.309 1.016–1.686 0.037
ABO-incompatible 1.214 0.934–1.577 0.15
Liver graft 0.005 0.013
Whole liver 1 1 1 1
Left-side liver graft 2.22 1.364–3.614 2.065 1.262–3.380
Right-side liver graft 1.283 0.989–1.664 1.275 0.981–1.657




Basiliximab induction 0.738 0.589–0.923 0.008 0.682 0.543–0.855 <0.001
Calcineurin inhibitors at discharge 1.975 0.702–9.402 0.228
Tacrolimus at discharge 0.876 0.467–1.643 0.68
Cyclosporine at discharge 1.994 1.064–3.737 0.031
Antimetabolite at discharge 0.721 0.580–0.896 0.003 0.692 0.554–0.863 0.001
Use of mTOR inhibitors at 6 months  
post-transplant
0.771 0.544–1.091 0.142
Steroid at discharge 2.979 1.777–4.993 <0.001 3.144 1.842–5.367 <0.001
Donor gender (male) 1.256 1.010–1.561 0.04
Donor age 0.992 0.985–1.000 0.04
Hypertension in donor 0.866 0.568–1.321 0.505
Diabetes in donor 0.818 0.437–1.533 0.531
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Table 3 Risk factors for NODAT in adult living donor liver transplant patients (n=1,473)
Variables
Univariate Multivariate
HR 95% CI P value HR 95% CI P value
Recipient gender (male) 1.188 0.916–1.541 0.193
Recipient age 1.021 1.008–1.035 0.002 1.025 1.011–1.040 <0.001
Hypertension in recipients 1.325 0.995–1.765 0.054
Body mass index in recipients 0.003 0.009
<18.5 1 1 1 1
18.5–24 0.76 0.440–1.314 0.732 0.438–1.327
25–29 1.025 0.586–1.791 0.985 0.580–1.808
≥30 1.525 0.806–2.887 1.376 0.729–2.715
Primary liver disease 0.271
Alcohol 1 1
Cryptogenic 1.03 0.610–1.737
Hepatitis B virus 0.814 0.613–1.082
Hepatitis C virus 0.798 0.483–1.318
Others 0.57 0.325–1.000




Acute on chronic 0.562 0.250–1.260
Child-Pugh class 0.018 0.043
A 1 1 1 1
B 1.417 1.094–1.836 1.112 0.836–1.483
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HR 95% CI P value HR 95% CI P value
ABO-incompatible 1.129 0.861–1.481 0.382
Liver graft 0.016
Left-side liver graft 1 1
Right-side liver graft 0.579 0.371–0.901




Living related donor 1.726 1.170–2.547 0.006
Minimal invasive donor hepatectomy 0.365 0.246–0.542 <0.001 0.397 0.257–5.858 <0.001
GRWR ≤0.8% 1.718 1.227–2.410 0.002 1.553 1.070–2.193 0.016
Basiliximab induction 0.603 0.471–0.772 <0.001 0.677 0.525–0.881 0.003
Calcineurin inhibitors at discharge 1.183 0.294–4.751 0.813
Tacrolimus at discharge 0.708 0.365–1.375 0.308
Cyclosporine at discharge 2.146 1.106–4.167 0.024
Antimetabolite at discharge 0.7 0.547–0.895 0.004 0.712 0.555–0.921 0.009
Use of mTOR inhibitors at 6 months  
post-transplant
0.719 0.481–1.074 0.107
Steroid at discharge 3.166 1.685–5.947 <0.001 3.802 2.080–7.986 <0.001
Donor gender (male) 1.224 0.962–1.559 0.101
Donor age 0.988 0.978–0.999 0.033
Hypertension in donors 1.144 0.567–2.309 0.707
Diabetes in donors 0.98 0.244–3.938 0.978





LT populations in Korea and Western countries differ 
in several aspects, such as race, diet, genetic background 
and etiology of liver diseases. HCV infection, obesity 
and alcoholic cirrhosis are the three major risk factors 
of NODAT in Western countries, but not in Korea. It is 
unclear if the incidence of NODAT in Korean transplant 
recipients is similar to that in Western countries. It is also 
unclear whether NODAT is related to the primary liver 
disease, donor liver, surgical procedures and/or the use of 
immunosuppressive treatments.
In our study, recipient risk factors for NODAT 
identified in adult post-transplant patients by multivariate 
analyses were increased age, high recipient BMI, steroid 
use, and left-side liver graft, while basiliximab induction 
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and antimetabolite use had a protective effect on the 
development of NODAT. In adult LDLT patients, risk 
factors for NODAT were increased recipient age, patients 
without HCC, high recipient BMI, advanced liver cirrhosis, 
steroid use, open donor hepatectomy, and small size liver 
grafts (GRWR ≤0.8), while basiliximab induction and 
antimetabolite use had a protective effect. 
Increased age is an established risk factor for NODAT in 
liver transplant recipients. A previous study reported older 
age as an independent predictor for NODAT in a cohort 
of 555 liver transplant recipients (25). A more recent study 
using OPTN/SRTR data also reported increased recipient 
age (≥50 years) as a risk factor for NODAT in a cohort 
of 15,463 liver transplant recipients (12). In this study, 
increased recipient age was an independent risk factor for 
NODAT in both adult LDLT and DDLT recipients. 
Obesity has been shown to be an independent risk factor 
for NODAT in LT. A previous multicenter study reported 
that a BMI greater than 25 kg/m2 was associated with an 
increased risk of NODAT (26). OPTN/SRTR data revealed 
that overweight/obesity (BMI ≥25 kg/m2) was associated 
with an 18.6% increased risk for NODAT in LT recipients 
after adjustment for other factors (12). Our study showed 
that obesity (recipient BMI ≥30 kg/m2) was an independent 
factor in adult LT and LDLT patients. However, the 
predictive effect of the recipient BMI should be interpreted 
with caution, due to severe ascites contributing to the high 
BMI values in some patients. Additionally, present study 
showed that non-HCC patients were related with NODAT. 
The median MELD score in HCC patients is lower than 
in the non-HCC patients (10 vs. 20, P<0.001). Additionally, 
the proportion of Child-Pugh class C in the HCC patients 
was lower than in the non-HCC patients (16.1% vs. 60.1%, 
P<0.001). Physical inactivity or poor performance might 
contribute NODAT development in terms of elderly 
recipient, obesity, and advanced liver cirrhosis.
Specific immunosuppressive regimens may influence the 
development of NODAT after solid organ transplantation. 
In liver recipients, maintenance immunosuppression with 
tacrolimus and steroid has been associated with an increased 
risk of NODAT (22-24,27). In this study, both tacrolimus 
and steroid use at discharge were associated with an 
increased risk of NODAT in LT recipients in univariate and 
multivariate analyses, whereas basiliximab induction therapy 
and use of antimetabolite at discharge were associated 
with a decreased risk. However, we found that the use of 
mammalian target of rapamycin inhibitors at 6 months was 
not associated with the risk of NODAT. 
Figure 2 Graft survival: (A) all adult LT patients, (B) DDLT 
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In present study, 76.9% of liver recipients had induction 
therapy. The incidence of NODAT was significantly lower 
in recipients who received induction therapy, compared 
with those who did not (P=0.008). In the multivariate 
analysis, induction therapy decreased the risk of NODAT 
in adult LT and LDLT recipients. Basiliximab induction 
reduced the risk of NODAT onset in adult LT and LDLT, 
with odd ratios of 0.682 and 0.677, respectively. We thought 
that basiliximab induction and antimetabolites allow to 
decrease tacrolimus exposure, thus resulting in reduced 
risk of NODAT. if needed. In meta-analysis studies, 
induction therapy with steroid-free immunosuppression has 
been shown to decrease the incidence of NODAT in LT 
recipients (23,24). 
Corticosteroids have a well-recognized diabetogenic 
effect; the main mechanism underlying this effect is insulin 
resistance, which causes increased hepatic gluconeogenesis 
(22-24,27). Meta-analyses of LT study data found that 
withdrawal of glucocorticoids after LT may reduce the 
risk of NODAT, and no unfavorable effects were observed 
after steroid withdrawal over short-term follow up (23,24). 
Suggested mechanisms for the hyperglycemia related to 
NODAT include increased insulin resistance, increased 
hepatic gluconeogenesis, and decreased insulin secretion (28). 
The risk of NODAT increases proportionally to both the 
dose and duration of corticosteroid therapy (22-24).
Previous studies have reported that antiproliferative 
agents and mTOR inhibitors do not cause hyperglycemia. 
However, our study revealed that use of antimetabolite 
reduced the incidence of NODAT, but mTOR inhibitors 
did not affect NODAT occurrence. The known side effects 
of calcineurin inhibitors include diabetes, possibly as a result 
of impaired insulin secretion and sensitivity, inhibition 
of insulin gene transcription and/or direct damage to 
pancreatic islet cells (29). There is evidence indicating 
the incidence of NODAT is greater in LT patients 
receiving tacrolimus compared with those treated with 
cyclosporine (11), but the reason for this difference is 
unclear (30). A recent study reported that a minimal 
tacrolimus regimen can decrease the risk of long-term 
NODAT after LT (21). Univariate analyses of our data 
found that cyclosporine usage predicted NODAT, but 
multivariate analyses found cyclosporine treatment did not 
predict NODAT in adult LT and LDLT patients. Our study 
did not demonstrate tacrolimus use or cyclosporine use were 
not risk factor for NODAT because many patients (97.3%) 
in our study population accounted for the tacrolimus. In 
addition, the combination of low dose calcineurin inhibitors 
and antimetabolite is commonly used for maintenance 
therapy in Korea. 
The associations between small size liver graft or 
minimally invasive donor hepatectomy in living donor 
hepatectomy and NODAT have rarely been examined 
in previous studies. Logistic regression analyses in the 
present study found that small size liver graft (GRWR 
≤0.8) or minimally invasive donor hepatectomy, including 
laparoscopic donor hepatectomy or robotic donor 
hepatectomy, in LDLT were independent risk factors for 
NODAT. Three to five centers performed the minimal 
invasive donor hepatectomy according to their indications. 
Laparoscopic donor hepatectomy in our center performed 
nearly all cases. The mechanism underlying the influence 
of these factors on the occurrence of NODAT in the LT 
recipients from living donor hepatectomy is unclear, but 
we speculate that hepatic inflammation may be involved. 
We cannot explain clearly the protective effect of minimal 
invasive donor hepatectomy in our study. More researches 
should be needed to define the relevance of small size 
liver graft or minimally invasive donor hepatectomy to 
developing NODAT.
Liver surgery induces acute hepatic inflammation, which 
is characterized by the production and release of various 
chemical mediators, including cytokines (31). An increase 
in lipid peroxidation was found to be important for normal 
proliferative processes to occur in the remnant liver after 
partial hepatectomy (31). The pathophysiology of hepatic 
ischemic-reperfusion injury is not only related to the direct 
cell impairment caused by ischemic insult, but also results 
from the restoration of blood flow, which triggers the pro-
inflammatory environment (32). Therefore, ischemic-
reperfusion injury is associated with inflammation and 
oxidation processes. Reactive oxygen species and oxidative 
stress in hepatic ischemic/reperfusion injury ultimately 
result in the production of lipid peroxidation (33). LT 
using small size liver grafts (GRWR ≤0.8) leads to rapid 
post-transplant liver regeneration, while obtaining liver 
grafts through open donor hepatectomy requires a large 
incision. Both small size liver grafts and large incision 
may induce greater production of reactive oxygen species 
and oxidative stress in the donors or recipients compared 
to LT using liver grafts procured by minimally invasive 
donor hepatectomy from living liver donors or using liver 
grafts with sufficient volumes. This topic requires further 
investigation.
The association of chronic liver disease with impaired 
glucose metabolism is well known. In cirrhotic patients, the 
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prevalence of impaired glucose tolerance is estimated to be 
approximately 60% to 80% (34). Analysis of OPTN/SRTR 
data indicated that pre-transplant cirrhosis (alcoholic or 
non-alcoholic) was an independent risk factor for NODAT 
in liver transplant recipients (12), but our data showed that 
pre-transplant cirrhosis or urgent status for liver transplant 
candidates could not predict NODAT in Korean LT 
recipients.
The findings from published studies regarding the effect 
of NODAT on graft failure or patient death after LT are 
inconsistent. Previous studies reported significantly lower 
survival rates of both recipients and grafts in the patients 
who developed NODAT compared to non-NODAT 
patients (2,11). However, other studies reported that the 1- 
and 2-year survival rates did not differ significantly between 
the two patient groups (7,12,35). Our study also found 
NODAT did not have an impact on patient survival. 
NODAT is a common and serious complication after LT 
in Western countries and China (10,12), however, it does 
not seem to influence graft survival in the adult Korean LT 
recipients in our study. One should note, however, that the 
follow-up duration in our study was relatively short. Timely 
intervention for treatment of hyperglycemia may prevent 
poor outcomes in patients who develop NODAT. In Korea, 
the government, academic expert groups, national insurance 
program, and hospitals are very active in the diagnosis, 
treatment, and management of diabetes, which may serve to 
reduce diabetes-related complications (36).
Our large prospective cohort study has several limitations 
that warrant consideration. First, the KOTRY database 
does not include actual medical examination data, such as 
physical examination findings and laboratory results, or 
intraoperative data, such as operative time, hemodynamics, 
or medications used during surgery that may be closely 
linked to the development of NODAT after LT. Other large 
transplant-related datasets may contain data not available 
in the KOTRY-based datasets. Second, the KOTRY 
database is heterogeneous and subject to flaws inherent in 
the nature of all registry databases such as reporting bias 
or error. NODAT is defined based on follow-up reporting 
to the KOTRY database. The actual incidence of NODAT 
is difficult to determine due to different definitions of 
NODAT being used by the 15 medical centers reporting 
transplant data to the KOTRY. The date of NODAT events 
reported to the KOTRY may be inconsistent with the actual 
date of NODAT onset. In addition, immunosuppression 
protocols and the management of NODAT in participating 
institutions are heterogeneous. Third, the follow-up 
period in our study was relatively short, with a median 
follow-up duration of about one year, therefore the effect 
of NODAT on end-stage renal disease, long-term graft 
and patient survival could not be assessed. Additionally, 
KOTRY database does not have information regarding 
diabetes therapy such as insulin or oral drugs, surveillance, 
or screening of vascular complications. Further studies 
using a longer follow-up time are needed to assess the long-
term effects of NODAT on cardiovascular events, graft and 
patient outcomes in LT.
Nonetheless, the present study is the first to assess 
the incidence of  NODAT in Korean LT patients 
included in the KOTRY database, and the results may be 
informative for future transplant patient management. 
In addition, our study is one of the largest prospective 
registry studies of NODAT following adult LT. These 
data are also meaningful in reflecting racial and social 
differences between western and Asian countries. Present 
study contributed the change of our center’s policy which 
included minimal invasive donor hepatectomy in nearly all 
LDLT cases and immunosuppressive protocols after LT.
In conclusion, the incidence of NODAT is about 20% 
within the first year after adult LT in Korean transplant 
recipients. Advanced recipient age, high BMI in recipient, 
and implantation of a left-side liver graft increased the 
risk of NODAT in adult LT patients, while basiliximab 
induction and use of antimetabolite decreased the risk of 
NODAT in these patients. Along with the same risk factors 
for NODAT in adult LT patients, small size liver grafts or 
open donor hepatectomy were also found to increase the 
risk of NODAT in LDLT recipients. The present study 
showed that NODAT did not affect graft survival over the 
relatively short follow-up period in patients who were not 
non-diabetic before transplantation. 
The findings indicate greater attention should be paid 
to monitoring and managing impaired glucose regulation 
after transplantation to prevent renal dysfunction, which 
should improve the long-tern survival and quality of life of 
LT recipients. Prospective studies are needed to identify 
whether modifiable risk factors are present before and/or 
after LT to reduce the incidence of NODAT.
Acknowledgments
We would like to thank the MRCC for data extraction and 
analysis. 
Kim et al. NODAT after adult LT in Korea438
© HepatoBiliary Surgery and Nutrition. All rights reserved.   HepatoBiliary Surg Nutr 2020;9(4):425-439 | http://dx.doi.org/10.21037/hbsn.2019.10.29
Funding: This research was supported by a fund by Research 
of Korea Centers for Disease Control and Prevention 
(2014-ER6301-00, 2014-ER6301-01, 2014-ER6301-02, 
2017-ER6301-00, 2017-ER6301-01). 
Footnote
Reporting Checklist: The authors have completed the 
STROBE reporting checklist. Available at http://dx.doi.
org/10.21037/hbsn.2019.10.29
Data Sharing Statement: Available at http://dx.doi.
org/10.21037/hbsn.2019.10.29
Conflicts of Interest: All authors have completed the ICMJE 
uniform disclosure form (available at http://dx.doi.
org/10.21037/hbsn.2019.10.29). The authors have no 
conflicts of interest to declare.
Ethical Statement: The authors are accountable for all 
aspects of the work in ensuring that questions related 
to the accuracy or integrity of any part of the work are 
appropriately investigated and resolved. This study was 
approved by the KOTRY, which is the only authorized 
national LT registry in South Korea. The study was initiated 
after obtaining approval from the ethics committee for 
each participating center, according to the Regulations on 
Human Organ Transplant and national legal requirements. 
The procedures were in accordance with the Helsinki 
declaration. All patients provided informed consent prior to 
participation in the study.
Open Access Statement: This is an Open Access article 
distributed in accordance with the Creative Commons 
Attribution-NonCommercial-NoDerivs 4.0 International 
License (CC BY-NC-ND 4.0), which permits the non-
commercial replication and distribution of the article with 
the strict proviso that no changes or edits are made and 
the original work is properly cited (including links to both 




1. Wallia A, Illuri V, Molitch ME. Diabetes Care After 
Transplant: Definitions, Risk Factors, and Clinical 
Management. Med Clin North Am 2016;100:535-50.
2. Moon JI, Barbeito R, Faradji RN, et al. Negative impact 
of new-onset diabetes mellitus on patient and graft 
survival after liver transplantation: Long-term follow up. 
Transplantation 2006;82:1625-8.
3. Baid S, Cosimi AB, Farrell ML, et al. Posttransplant 
diabetes mellitus in liver transplant recipients: risk factors, 
temporal relationship with hepatitis C virus allograft 
hepatitis, and impact on mortality. Transplantation 
2001;72:1066-72.
4. Lv C, Zhang Y, Chen X, et al. New-onset diabetes after 
liver transplantation and its impact on complications and 
patient survival. J Diabetes 2015;7:881-90.
5. Li DW, Lu TF, Hua XW, et al. Risk factors for new onset 
diabetes mellitus after liver transplantation: A meta-
analysis. World J Gastroenterol 2015;21:6329-40.
6. Sarno G, Mehta RJ, Guardado-Mendoza R, et al. New-
onset diabetes mellitus: predictive factors and impact on 
the outcome of patients undergoing liver transplantation. 
Curr Diabetes Rev 2013;9:78-85.
7. Yagi S, Kaido T, Iida T, et al. New-onset diabetes mellitus 
after living-donor liver transplantation: association with 
graft synthetic function. Surg Today 2017;47:733-42.
8. Gebhardt S, Jara M, Malinowski M, et al. Risk factors 
of metabolic disorders after liver transplantation: an 
analysis of data from fasted patients. Transplantation 
2015;99:1243-9.
9. Parekh J, Corley DA, Feng S. Diabetes, hypertension and 
hyperlipidemia: prevalence over time and impact on long-
term survival after liver transplantation. Am J Transplant 
2012;12:2181-7.
10. Ling Q, Xu X, Xie H, et al. New-onset diabetes after 
liver transplantation: a national report from China Liver 
Transplant Registry. Liver Int 2016;36:705-12.
11. Xu X, Ling Q, He ZL, et al. Post-transplant diabetes 
mellitus in liver transplantation: Hangzhou experience. 
Hepatobiliary Pancreat Dis Int 2008;7:465-70.
12. Kuo HT, Sampaio MS, Ye X, et al. Risk factors for new-
onset diabetes mellitus in adult liver transplant recipients, 
an analysis of the Organ Procurement and Transplant 
Network/United Network for Organ Sharing database. 
Transplantation 2010;89:1134-40.
13. Chapman J. Transplantation practice has been particularly 
suited to national, regional, specialist and global registries. 
Transplant Rev (Orlando) 2013;27:37.
14. Massie AB, Kucirka LM, Segev DL. Big data in organ 
transplantation: registries and administrative claims. Am J 
Transplant 2014;14:1723-30.
15. Lee JG, Lee KW, Kwon CHD, et al. Donor safety 
HepatoBiliary Surgery and Nutrition, Vol 9, No 4 August 2020 439
© HepatoBiliary Surgery and Nutrition. All rights reserved.   HepatoBiliary Surg Nutr 2020;9(4):425-439 | http://dx.doi.org/10.21037/hbsn.2019.10.29
in living donor liver transplantation: The Korean 
organ transplantation registry study. Liver Transpl 
2017;23:999-1006.
16. Yang J, Jeong JC, Lee J, et al. Design and Methods of the 
Korean Organ Transplantation Registry. Transplant Direct 
2017;3:e191.
17. American Diabetes Association. Diagnosis and 
classification of diabetes mellitus. Diabetes Care 2012;35 
Suppl 1:S64-71.
18. Levey AS, Inker LA, Coresh J. GFR estimation: 
from physiology to public health. Am J Kidney Dis 
2014;63:820-34.
19. Min SI, Ahn C, Han DJ, et al. To achieve national self-
sufficiency: recent progresses in deceased donation in 
Korea. Transplantation 2015;99:765-70.
20. Boo S, Yoon YJ, Oh H. Evaluating the prevalence, 
awareness, and control of hypertension, diabetes, and 
dyslipidemia in Korea using the NHIS-NSC database: 
A cross-sectional analysis. Medicine (Baltimore) 
2018;97:e13713.
21. Song JL, Gao W, Zhong Y, et al. Minimizing tacrolimus 
decreases the risk of new-onset diabetes mellitus after liver 
transplantation. World J Gastroenterol 2016;22:2133-41.
22. Kim YK, Lee KW, Kim SH, et al. Early steroid withdrawal 
regimen prevents new-onset diabetes mellitus in old-age 
recipients after living donor liver transplantation. World J 
Surg 2012;36:2443-8.
23. Sgourakis G, Radtke A, Fouzas I, et al. Corticosteroid-
free immunosuppression in liver transplantation: a meta-
analysis and meta-regression of outcomes. Transpl Int 
2009;22:892-905.
24. Segev DL, Sozio SM, Shin EJ, et al. Steroid avoidance in 
liver transplantation: meta-analysis and meta-regression of 
randomized trials. Liver Transpl 2008;14:512-25.
25. Khalili M, Lim JW, Bass N, et al. New onset diabetes 
mellitus after liver transplantation: the critical role of 
hepatitis C infection. Liver Transpl 2004;10:349-55.
26. Saliba F, Lakehal M, Pageaux GP, et al. Risk factors for 
new-onset diabetes mellitus following liver transplantation 
and impact of hepatitis C infection : an observational 
multicenter study. Liver Transpl 2007;13:136-44.
27. Oufroukhi L, Kamar N, Muscari F, et al. Predictive factors 
for posttransplant diabetes mellitus within one-year of 
liver transplantation. Transplantation 2008;85:1436-42.
28. van Raalte DH, Ouwens DM, Diamant M. Novel insights 
into glucocorticoid-mediated diabetogenic effects: towards 
expansion of therapeutic options? Eur J Clin Invest 
2009;39:81-93.
29. Markell M. New-onset diabetes mellitus in transplant 
patients: pathogenesis, complications, and management. 
Am J Kidney Dis 2004;43:953-65.
30. Heisel O, Heisel R, Balshaw R, et al. New onset diabetes 
mellitus in patients receiving calcineurin inhibitors: a 
systematic review and meta-analysis. Am J Transplant 
2004;4:583-95.
31. Mendes-Braz M, Martins JO. Diabetes Mellitus and Liver 
Surgery: The Effect of Diabetes on Oxidative Stress and 
Inflammation. Mediators Inflamm 2018;2018:2456579.
32. Donadon M, Molinari AF, Corazzi F, et al. 
Pharmacological Modulation of Ischemic-Reperfusion 
Injury during Pringle Maneuver in Hepatic Surgery. 
A Prospective Randomized Pilot Study. World J Surg 
2016;40:2202-12.
33. Rehman K, Akash MSH. Mechanism of Generation of 
Oxidative Stress and Pathophysiology of Type 2 Diabetes 
Mellitus: How Are They Interlinked? J Cell Biochem 
2017;118:3577-85.
34. Konrad T, Steinmuller T, Vicini P, et al. Evidence for 
impaired glucose effectiveness in cirrhotic patients after 
liver transplantation. Metabolism 2000;49:367-72.
35. John PR, Thuluvath PJ. Outcome of liver transplantation 
in patients with diabetes mellitus: a case-control study. 
Hepatology 2001;34:889-95.
36. Ko SH, Han K, Lee YH, et al. Past and Current Status of 
Adult Type 2 Diabetes Mellitus Management in Korea: 
A National Health Insurance Service Database Analysis. 
Diabetes Metab J 2018;42:93-100.
Cite this article as: Kim JM, Hwang S, Lee KW, Lee JG, 
Ryu JH, Kim BW, Choi DL, You YK, Kim DS, Nah YW, 
Kang KJ, Cho JY, Hong G, Choi IS, Yu HC, Choi D, Kim MS; 
The Korean Organ Transplantation Registry Study Group. 
New-onset diabetes after adult liver transplantation in the 
Korean Organ Transplantation Registry (KOTRY) study. 
HepatoBiliary Surg Nutr 2020;9(4):425-439. doi: 10.21037/
hbsn.2019.10.29
Table S1 The risk factors for NODAT in adult deceased donor liver transplant patients (n=446)
Factors
Univariate Multivariate
HR 95% CI P value HR 95% CI P value
Recipient gender (male) 1.066 0.660–1.723 0.794
Recipient age 1.028 1.004–1.051 0.02 1.028 1.005–1.052 0.020
Hypertension in recipient 1.278 0.657–2.486 0.471








Hepatitis B virus 1.07 0.627–1.828
Hepatitis C virus 1.838 0.882–3.828
Others 1.254 0.565–2.780













Urgent status in KONOS 0.505
1 1 1






Whole liver 1 1
Left-side liver graft 2.38 0.019–16.396
Right-side liver graft 1.597 0.526–3.700




Basiliximab induction 1.47 0.856–2.523 0.163
Calcineurin inhibitors at discharge 2.836 0.410–358.067 0.377
Tacrolimus at discharge 1.627 0.226–11.717 0.629
Cyclosporine at discharge 1.127 0.157–8.107 0.906
Antimetabolite at discharge 0.715 0.446–1.146 0.163
Use of mTOR inhibitors at 6 months post-
transplant
1.01 0.503–2.029 0.977
Steroid at discharge 2.162 0.872–5.357 0.096
Donor gender (male) 1.447 0.874–2.396 0.151
Donor age 1.008 0.993–1.023 0.31
Hypertension in donor 0.914 0.519–1.609 0.755
Diabetes in donor 0.955 0.459–1.988 0.902
Body mass index in donor 0.503
<18.5 1 1
18.5–24 0.732 0.330–1.624
25–29 1.025 0.436–2.413
≥30 0.51 0.106–2.455
Supplementary
